FibroBiologics Inc. (NASDAQ:FBLG) Short Interest Update

FibroBiologics Inc. (NASDAQ:FBLG) saw a significant decline in short interest in the month of January. As of January 15th, there was short interest totaling 372,855 shares, a decline of 58.9% from the December 31st total of 907,076 shares. Based on an average trading volume of 2,493,848 shares, the short-interest ratio is currently 0.1 days. Currently, 0.6% of the shares of the company are short sold. Currently, 0.6% of the shares of the company are short sold. Based on an average trading volume of 2,493,848 shares, the short-interest ratio is currently 0.1 days.

FibroBiologics Stock Performance

Shares of NASDAQ FBLG traded down $0.01 during midday trading on Friday, reaching $0.33. The stock had a trading volume of 508,378 shares, compared to its average volume of 1,579,030. The company’s 50 day moving average price is $0.30 and its 200 day moving average price is $0.44. FibroBiologics has a twelve month low of $0.22 and a twelve month high of $2.00. The firm has a market cap of $22.07 million, a price-to-earnings ratio of -0.69 and a beta of -0.54.

FibroBiologics (NASDAQ:FBLG) last announced its earnings results on Friday, October 31st. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.03). Equities analysts forecast that FibroBiologics will post -0.53 earnings per share for the current fiscal year.

Insider Activity at FibroBiologics

In other FibroBiologics news, General Counsel Ruben A. Garcia acquired 140,000 shares of the company’s stock in a transaction on Thursday, December 11th. The stock was acquired at an average price of $0.34 per share, for a total transaction of $47,600.00. Following the purchase, the general counsel directly owned 140,000 shares of the company’s stock, valued at $47,600. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 13.00% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in FBLG. Yorkville Advisors Global LP acquired a new position in FibroBiologics during the third quarter worth $278,000. Landscape Capital Management L.L.C. bought a new position in shares of FibroBiologics in the third quarter valued at approximately $191,000. Cascade Financial Partners LLC increased its position in shares of FibroBiologics by 11.7% during the 2nd quarter. Cascade Financial Partners LLC now owns 290,581 shares of the company’s stock valued at $181,000 after purchasing an additional 30,500 shares during the last quarter. AMG National Trust Bank bought a new stake in FibroBiologics in the fourth quarter worth about $31,000. Finally, Cerity Partners LLC lifted its stake in FibroBiologics by 37.2% in the second quarter. Cerity Partners LLC now owns 128,109 shares of the company’s stock valued at $80,000 after purchasing an additional 34,702 shares during the last quarter.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. D. Boral Capital reissued a “buy” rating and set a $15.00 price objective on shares of FibroBiologics in a report on Tuesday, January 6th. Weiss Ratings restated a “sell (e+)” rating on shares of FibroBiologics in a report on Thursday, January 22nd. Finally, HC Wainwright reiterated a “buy” rating and issued a $5.00 price objective on shares of FibroBiologics in a report on Friday, January 2nd. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, FibroBiologics presently has a consensus rating of “Hold” and a consensus price target of $10.00.

About FibroBiologics

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc was incorporated in 2021 and is based in Houston, Texas.